Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

BACKGROUND: Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physician factors impact treatment decisions. The purpose of this study was to exami...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwedhelm, Thomas M., Rees, Judy R., Onega, Tracy, Zipkin, Ronnie J., Schaefer, Andrew, Celaya, Maria O., Moen, Erika L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650301/
https://www.ncbi.nlm.nih.gov/pubmed/32883270
http://dx.doi.org/10.1186/s12885-020-07355-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650301/
https://www.ncbi.nlm.nih.gov/pubmed/32883270
http://dx.doi.org/10.1186/s12885-020-07355-6

Ejemplares similares